KRISS Unveils Innovative Nanomedicine for Cancer Detection and Treatment

Researchers at the Korea Research Institute of Standards and Science (KRISS) have developed a groundbreaking nanomedicine capable of simultaneously detecting and treating cancer through a multifaceted approach. This innovative nanomaterial, consisting of a gold-iron-gold sandwich structure, demonstrated significant potential in pre-clinical studies published in the *Chemical Engineering Journal* on July 3, 2025.

In laboratory tests conducted with mice, the novel gold-iron nanoparticles enabled real-time tumor imaging while simultaneously delivering targeted treatments via heat, chemical reactions, and immune system activation. Dr. Lee Eun Sook, a lead researcher at KRISS, explained that the unique structure of these nanoparticles allows for the delivery of three complementary therapies, marking a substantial advancement over conventional nanomaterials that typically offer a single treatment modality.

The outer gold layers of the nanoparticles facilitate the destruction of cancer cells through heat when activated by laser light. The iron core enhances the particles' magnetic guidance capabilities and triggers chemical reactions that damage tumor cells through oxidation and ferroptosis. Such a multi-functional approach offers a significant improvement in treatment effectiveness and precision.

According to the study's findings, the photo-acoustic imaging capabilities of the gold-iron nanoparticles provide an accurate localization of tumor tissue, which is crucial for guiding the photothermal therapy (PTT). The researchers noted that their method not only eliminates tumor cells but also initiates immunogenic cell death (ICD) by releasing damage-associated molecular patterns (DAMPs) in tumor-bearing mice. This process stimulates an anti-tumor immune response, potentially enhancing the overall effectiveness of the treatment.

The KRISS breakthrough builds upon a growing body of international research into multifunctional nanoparticles for cancer therapy. For instance, a team from Georgia Institute of Technology and Emory University has developed Janus cellular backpacks that can deliver therapeutic payloads into cells, while other researchers are exploring gold-copper sulfide hybrids that combine near-infrared imaging with chemical therapy.

Despite these advancements, many existing strategies rely on core-shell or surface-modified designs. In contrast, KRISS's trilayer architecture achieved through nanoimprint lithography may offer enhanced stability and controlled therapeutic delivery.

The implications of this research are profound, as effective real-time imaging combined with targeted cancer therapies could revolutionize cancer treatment methodologies. As KRISS prepares for potential human trials, the medical community eagerly anticipates further developments that could enhance treatment outcomes for cancer patients.

In conclusion, the innovative work being done at KRISS showcases the potential of nanotechnology in the fight against cancer. With ongoing research and development, the future of cancer treatment may be significantly transformed, paving the way for more effective and personalized therapeutic options.